{"name":"Plus Therapeutics","slug":"plus-therapeutics","ticker":"","exchange":"","domain":"","description":"Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system (CNS) cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecular diagnostic service, CNSide®.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":5213000,"revenueGrowth":-10.5,"grossMargin":0,"rdSpend":8379000,"netIncome":-22386000,"cash":16325000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"date":"2026-04-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNbERFdFpSY3lmSnB1LV9iQ3R0S1luMnpURXlkMUZ0bW9JRnRxdndJemRhX1pWemZxczlSUGs4b2dYdnpMM2N2VGg4YWZtanFzeDdlcHViblg2OHJWVk5xU2NuX2JrSWVNNVZ4YXJvX2VSck1vNWZzMG94VjVTc3djY1BrRnUwWDRkTG5TcHdaNzY1ai04Tks0NjJ6Y1BKRUpoNFBBMzhnTDJnX2RXeWxhX3hEdmVMMVBjU0Vn?oc=5","date":"2026-03-31","type":"pipeline","source":"GlobeNewswire","summary":"Plus Therapeutics Announces Reverse Stock Split - GlobeNewswire","headline":"Plus Therapeutics Announces Reverse Stock Split","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQSWxFQmNIQnNhTEtFTmR4Q1QxSTIyMUZNS3JKVWZMTnVuaVp0a1JTT18wWEE3SVNEX3pxamx5ZWJTYnlNWkl6a2k3dW54cGNNWXZGSnNCQnVSMzVXZjJyS0w3S3FYSEZ0akNSeUd0cEtOcDRnSjNxR3VkRFhKbHpVN1B5TngtU0FLb01MU21YYW1jT1JMaFJ1aFFqOWZDNGlfRFZYQjhEOA?oc=5","date":"2026-03-31","type":"pipeline","source":"National Today","summary":"Plus Therapeutics Announces Reverse Stock Split - National Today","headline":"Plus Therapeutics Announces Reverse Stock Split","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE8wWUFqZzVqT3hYc2toek5FcFVES1FNcDFpZG5WNVgtWDZ0amV5MVdFN2w0X0FnM3lQaUVSMmpxT1AzNXFhcHVnMzZiQTFyN3NkbmtRSHRKRktUTVFmZXfSAWNBVV95cUxPVS1nRmJ5Sk4ySXoxQWRFVmlMSERkQXk3MU14ZERGNDliVWtrbjVFNV9hM3p6V3JXNjc4SjhpV0RWelB1czMxSHdDVG1qWHozTFVFd1N1VWpCVkstZjYyYThqWm8?oc=5","date":"2026-03-30","type":"pipeline","source":"Bitget","summary":"Plus Therapeutics Announces Reverse Stock Split - Bitget","headline":"Plus Therapeutics Announces Reverse Stock Split","sentiment":"neutral"},{"date":"2026-03-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxNSmpXQmZkMUZEOFVJQXVZbTlnVXVIX2hGZzRSb0NjNURvN3lySm5jaGhBWGJXemxQZW1TNVRnMm9oVl9UQWFLSXM1cmhmdDZINWxDMW9DVTJ2dzBpMWM5aUxxMHpXR3B2UnRRVG03ZDAxaU5Tb0l4b3hKcXRsVFFIeC0zbkZaM1Rib1FPa0tGNTJ1MnF2Z3pkWjJCNnZBZTRNU010VGxZM2FER0Q5TnhvQ3JnUklaOEVNbFZrQklzV3BNeDBhMUMxNTdNLV9OSlpGUzBILTZxR3hWM2ZVS0Y0cV9XTkw0bllIVW9KZDd1dVVwcnJiNnRxYWNmbUd2WHB2S0pv?oc=5","date":"2026-03-17","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Plus Therapeutics (PSTV) - The Globe and Mail","headline":"Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Plus Therapeutics (PSTV)","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-12","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPQ3dybnZpeERvWXVIQkh4LUNYQzd1WFp6Q3lXUnJkUEg0bjcweE4yNWI3SWU0NkdEbWREN0pPN1FVSV8wYXFTQk1Jc0dkcm13T0xMSGFRaVpwQ1M5Uko3bG9HOGNWZ2s3dURONkFJeEJ2VkRjSmJqaGQxMF9GV19MazRxNENHc0RMVUFxZVc2N0NjeUNELTFyWEVjVFVHcVlSX1pTQ3NEOE1mamRsRFBBTExB?oc=5","date":"2026-03-06","type":"deal","source":"The Pharma Letter","summary":"Tenaya Therapeutics inks $1 billion-plus research deal with Alnylam - The Pharma Letter","headline":"Tenaya Therapeutics inks $1 billion-plus research deal with Alnylam","sentiment":"neutral"},{"date":"2026-02-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNTlFzcncyUnhSRVlRQ0hRQkFxcU9zWHBRNXc4TUQ2UmFwRGJHZXR3UnhBNDluUFppTG9xMDdTb19oZzBZSm1RZHZQaEcxalpjV3FMd1hiWmMtc21mYlpGYTgyOVQzS2htcGlxcGtQTS1Pem5GLXhnQkx6Ull4REFzTnh4ajM1bHgtOHk2d3ZWTHdNLTdUSUhManlXcEw5WlFSLUVfbkoyQVMtdlpPaFZodFhmSWktT2htSTRMN2p3ODUydw?oc=5","date":"2026-01-26","type":"pipeline","source":"PharmaTimes","summary":"Corcept Therapeutics’ relacorilant plus nab-paclitaxel shows positive results in ovarian cancer - PharmaTimes","headline":"Corcept Therapeutics’ relacorilant plus nab-paclitaxel shows positive results in ovarian cancer","sentiment":"neutral"},{"date":"2026-01-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":5213000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":5213000,"period":"2025-12-31"},{"value":5824000,"period":"2024-12-31"},{"value":5824000,"period":"2024-12-31"},{"value":4913000,"period":"2023-12-31"},{"value":2689000,"period":"2017-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":8379000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-22386000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":16325000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}